The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Open accessAbstract
Purpose: Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1–blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods: KEYNOTE-087 ( ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with rrHL, defined on the basis of lymphoma progression after (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV); (2) salvage chemotherapy and BV, and thus, ineligible for ASCT because of chemoresistant disease; and (3) ASCT, but without BV after transplantation. Patients received pembrolizumab 200 mg once every 3 weeks. Response was assessed every 12 weeks. The primary end points were ORR by central review and safety. Results: A total of 210 patients were enrolled and treated (69 in cohort 1, 81 in cohort 2, and 60 in cohort 3). At the time of analysis, patients received a median of 13 treatment cycles. Per central review, the ORR was 69.0% (95% CI, 62.3% to 75.2%), and the complete response rate was 22.4% (95% CI, 16.9% to 28.6%). By cohort, ORRs were 73.9% for cohort 1, 64.2% for cohort 2, and 70.0% for cohort 3. Thirty-one patients had a response ≥ 6 months. The safety profile was largely consistent with previous pembrolizumab studies. Conclusion: Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with rrHL, offering a new treatment paradigm for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Self-citationYounes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30167-x · Cited by 927
Self-citationPD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Self-citationMoskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60165-9 · Cited by 742
Self-citationThe biology of Hodgkin's lymphoma
Küppers, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2542 · Cited by 688
Green, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
Self-citationArmand, P., Shipp, M. A., Ribrag, V., Michot, J.-M., Zinzani, P. L., Kuruvilla, J., Snyder, E. S., Ricart, A. D., Balakumaran, A., Rose, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3467 · Cited by 670
Self-citationSystematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Chatterjee, M., Turner, D. C., Felip, E., Lena, H., Cappuzzo, F., Horn, L., Garon, E. B., Hui, R., Arkenau, H.-T., Gubens, M. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw174 · Cited by 172
Hodgkin lymphoma: Pathology and biology
Mathas, S., Hartmann, S., & Küppers, R. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.05.007 · Cited by 148
Treatment of advanced-stage Hodgkin lymphoma
Vassilakopoulos, T. P., & Johnson, P. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.05.006 · Cited by 26
Self-citation
Cited by
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Metadata
- Authors
- Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Zhang, Y., Ricart, A. D., Balakumaran, A., Moskowitz, C. H., & KEYNOTE-087, F. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-07-01
- Volume
- 35
- Issue
- 19
- Pages
- 2125-2132
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2609973112
- Cited by
- 989
- References
- 11
- FWCI
- 100.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.